source
- Revolution Medicines secures FDA approval for Rasonque, a RAS inhibitor targeting advanced pancreatic cancerRevolution Medicines announced FDA approval of its RAS inhibitor Rasonque for patients with advanced pancreatic cancer, marking a milestone for the company. The approval is seen as a breakthrough…
- Yarrow Bioscience raises $150M as AbbVie reports positive menstrual migraine trial resultsYarrow Bioscience, based in New Haven, announced pricing of a $150 million equity offering at $26 per share, roughly $2.50 below the previous closing price. The capital raise will provide addition…